Gustavo Ismael

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Planning cancer control in Latin America and the Caribbean

Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević et al. · The Lancet Oncology · 2013 · 496 citations · Full text

Preventive Medicine, Medicine, Global Health +7

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 337 citations

Hannah Study, Breast Oncology, Oncology +6

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Marion van Mackelenbergh, Sibylle Loibl, Michael Untch et al. · Journal of Clinical Oncology · 2023 · 90 citations

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 83 citations · Full text